EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy

Fatima Zahra Marok, Jan-Georg Wojtyniak iD, Dominik Selzer iD, Robert Dallmann, Jesse J Swen iD, Henk-Jan Guchelaar iD, Matthias Schwab iD, Thorsten Lehr iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Fatima Zahra Marok und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy, Saarland University, Saarbruecken, Germany. Hauptthemen laut MEDLINE: Fluorouracil, Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic, Models, Biological. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of circadian clock genes greatly amplified the study of diurnal variations impacting cancer therapy, transforming it into a rapidly growing field of research. Especially, use of chronomodulated treatment with 5‐fluorouracil (5‐FU) has gained significance. Studies indicate high interindividual variability (IIV) in diurnal variations in dihydropyrimidine dehydrogenase (DPD) activity – a key enzyme for 5‐FU metabolism. However, the influence of individual DPD chronotypes on chronomodulated therapy remains unclear and warrants further investigation. To optimize precision dosing of chronomodulated 5‐FU, this study aims to: (i) build physiologically‐based pharmacokinetic (PBPK) models for 5‐FU, uracil, and their metabolites, (ii) assess the impact of diurnal variation on DPD activity, (iii) estimate individual DPD chronotypes, and (iv) personalize chronomodulated 5‐FU infusion rates based on a patient's DPD chronotype. Whole‐body PBPK models were developed with PK‐Sim (R) and MoBi (R) . Sinusoidal functions were used to incorporate variations in enzyme activity and chronomodulated infusion rates as well as to estimate individual DPD chronotypes from DPYD mRNA expression or DPD enzymatic activity. Four whole‐body PBPK models for 5‐FU, uracil, and their metabolites were established utilizing data from 41 5‐FU and 10 publicly available uracil studies. IIV in DPD chronotypes was assessed and personalized chronomodulated administrations were developed to achieve (i) comparable 5‐FU peak plasma concentrations, (ii) comparable 5‐FU exposure, and (iii) constant 5‐FU plasma levels via “noise cancellation” chronomodulated infusion. The developed PBPK models capture the extent of diurnal variations in DPD activity and can help investigate individualized chronomodulated 5‐FU therapy through testing alternative personalized dosing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorouracilDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticModels, BiologicalPrecision MedicineNeoplasmsCircadian RhythmHumansDrug ChronotherapyMaleFemaleComputer SimulationMiddle AgedUracil

Substanzen

FluorouracilDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticUracil

Autor:innen und Institutionen

  • Clinical Pharmacy, Saarland University, Saarbruecken, Germany.
  • Dr. Margarete Fischer-Bosch-Institut of Clinical Pharmacology, Stuttgart, Germany.
  • Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
  • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, RC Leiden, The Netherlands.
  • Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy, University Tuebingen, Tuebingen, Germany.
  • Cluster of excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University Tuebingen, Tuebingen, Germany.

ORCID-Profile: Jan-Georg Wojtyniak, Dominik Selzer, Jesse J Swen, Henk-Jan Guchelaar, Matthias Schwab, Thorsten Lehr

Förderung

  • Cancer Research UK

Zitieren

APA

Marok, F. Z., Wojtyniak, J. G., Selzer, D., Dallmann, R., Swen, J. J., Guchelaar, H. J., Schwab, M., & Lehr, T. (2024). Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3181

Vancouver

Marok FZ, Wojtyniak JG, Selzer D, Dallmann R, Swen JJ, Guchelaar HJ, et al. Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3181

BibTeX
@article{Marok2024,
  author = {Marok, Fatima Zahra and Wojtyniak, Jan-Georg and Selzer, Dominik and Dallmann, Robert and Swen, Jesse J and Guchelaar, Henk-Jan and Schwab, Matthias and Lehr, Thorsten},
  title = {Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3181}
}
Kostenlos starten →